亚虹医药跌4.88% 2022年上市即巅峰募资25.28亿元

Core Viewpoint - Yahui Pharmaceutical (688176.SH) is currently experiencing a decline in stock price, closing at 11.51 yuan with a drop of 4.88%, indicating a state of share price below the initial public offering (IPO) price [1] Summary by Relevant Sections Company Overview - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at an IPO price of 22.98 yuan per share [1] - The company is controlled by PAN KE, who serves as the chairman and general manager, holding American nationality [1] IPO Details - The total funds raised from the IPO amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net funds raised exceeded the original plan by 311 million yuan, which was initially set at 2.070 billion yuan [1] - The total issuance costs were 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Stock Performance - The stock price fell below the IPO price on the first day of trading, with an intraday high of 20.00 yuan, marking the highest price since the listing [1]